No exosome product is FDA-approved, and the published studies do not describe what was in the vial well enough for anyone to repeat them.
Billions of regenerative exosomes delivered into the skin — the next generation of cellular rejuvenation, dramatically accelerating recovery and remodelling.
The market's own words. No brand is named, because the claim is the thing under examination and it belongs to dozens of them.
In adults having a resurfacing or microneedling procedure, does an exosome preparation applied to the treated skin, compared with the same procedure without it, measurably improve recovery time or skin quality — using a product whose contents are specified well enough for another clinic to reproduce?
The same claim written as a proposition somebody could go and check: who, compared with what, measured how, over how long.
What kind of missing this is
Something was tested, but what was tested is not specified well enough for anyone to reproduce it — source, dose, concentration, particle, batch. The result belongs to one jar, not to a category.
The evidence base here is not thin any more, and anyone still saying "only a dozen studies" is working from a 2025 picture. A systematic review and meta-analysis in Aesthetic Surgery Journal in March 2026 pooled 39 human clinical trials, 26 on skin and 13 on hair. That is a real literature and it is growing quickly.
The problem is not quantity. It is that nobody can tell you what was in the bottles.
An exosome preparation is defined by its source cell, its isolation method, its particle count, its purity, and what else came along with it. Those variables are not standardised across the field, are frequently unreported, and differ between products sold under the same word. Two clinics offering "exosome therapy" may be applying materially different things. A meta-analysis pooling trials of unspecified preparations produces a number, and the number is about the word rather than about a substance.
The earlier reviews say the same in their own conclusions. A 2025 review in the International Journal of Molecular Sciences asked, in its title, whether there is enough evidence from clinical trials. A 2026 systematic review in Dermatology Practical & Conceptual screened 1,032 papers, included 21, and closed by calling for standardised trials with larger cohorts and longer follow-up.
That is the actual state of it: an accumulating literature about a category whose members have not been characterised.
A randomised, split-face trial in at least 100 adults undergoing a standardised resurfacing procedure, comparing one fully specified exosome preparation — source cell line named, isolation method described, particle count and purity stated in the paper — against the same procedure with vehicle alone. Endpoints measured by instrument and by blinded assessors: erythema resolution time, transepidermal water loss recovery, and a validated skin-quality scale at three months.
The specification is the whole point of that paragraph. A trial that reports "exosome serum applied post-procedure" adds a row to a meta-analysis and adds nothing to what anyone knows, because the next clinic cannot tell whether they are selling the thing that was tested.
Two such trials, on preparations that could be told apart from each other, and this entry moves. A regulatory approval of a specific product would move it faster, because approval requires exactly the characterisation that is missing.
It does not mean exosomes are biological nonsense. Extracellular vesicles are real, they carry signalling cargo, and the mechanism is one of the more plausible in aesthetic medicine.
It does not mean the 39 trials found nothing. Several found something. It means the something cannot be attributed to a defined substance.
It does not mean your practitioner is dishonest. Most are buying a product from a supplier, in good faith, on the strength of the supplier's own material — which is where the characterisation gap actually starts.
And it does not mean this will still be true in three years. Of everything in this register, this is the entry most likely to change, and it will change the moment somebody publishes a trial of a named, specified preparation.
You are paying, usually several hundred pounds or dollars on top of a procedure that already cost money, for a vial whose contents are not disclosed to a standard that would let anyone verify them. That sentence is the whole decision.
What you are not paying for is an approved product, or a characterised one, or one that the evidence can be pointed at specifically.
There are two questions worth asking in the chair, and they are cheap to ask. What is the source of these exosomes, and can I see the supplier's specification sheet? A clinic that can answer both is operating several levels above the field average, and the answer tells you what you are getting. A clinic that cannot has bought the word.
And note where the money sits: the procedure underneath — the resurfacing, the microneedling — is the part with the evidence. The add-on is the part without it. If the budget is finite, that ordering matters more than anything on the brochure.
Type and funding are stated because they change what a study is allowed to prove, and because a trial paid for by the company selling the thing is not disqualified — it is just not the same evidence as one that was not.